TAVR Rewrites Structural Heart Care as Heart Valve Devices Market Projects 11.2% CAGR Through 2032
核心洞察
The global heart valve devices market was valued at USD 11.87 billion in 2025 and is forecast to reach USD 24.95 billion by 2032, expanding at an 11.2% CAGR.
Transcatheter aortic valve replacement (TAVR) is the strongest adoption signal, with over 80,000 U.S. procedures performed annually in 2023 and projections exceeding 190,000 by 2029.
TAVR procedures demonstrate a 30-day mortality rate of approximately 2–3%, compared with 5–8% for traditional open-heart surgery, reshaping the hospital business case.
The global heart valve devices market is undergoing a fundamental transformation as transcatheter aortic valve replacement (TAVR) reshapes structural heart care, driving the market from USD 11.87 billion in 2025 toward a projected USD 24.95 billion by 2032, according to analysis from Maximize Market Research (MMR). The 11.2% compound annual growth rate reflects aging populations, expanding regulatory approvals, and a decisive shift toward minimally invasive valve replacement.
"Cardiac providers face a widening gap between valve disease burden and surgical capacity," MMR reports. "Payers, hospital networks, device companies, and regulators now have to decide how quickly they can shift eligible patients from open surgery to minimally invasive repair and replacement."
The Clinical Case for TAVR
TAVR's clinical profile is compelling. MMR data indicate that TAVR procedures carry a 30-day mortality rate of approximately 2–3%, compared with 5–8% for traditional open-heart surgery. This mortality gap translates into faster recovery, shorter discharge timelines, and lower complication risk—factors that support higher hospital throughput and strengthen the business case for structural heart program investment.
In the United States, more than 80,000 TAVR procedures were performed annually in 2023, and MMR projects that figure could exceed 190,000 per year by 2029. The U.S. Food and Drug Administration's 2019 approval of TAVR for low-risk patients has been a pivotal catalyst, with the procedure now accounting for more than one-third of the total U.S. heart surgery market.
Disease Burden and Patient Dynamics
The patient population driving demand is substantial. Approximately 2.5% of Americans, primarily older adults, have heart valve disease, with roughly 28,000 annual deaths attributed to the condition. More than 2 million people in the United States have a leaking heart valve, and 1.5 million are affected by aortic stenosis (搜索). This disease burden places sustained pressure on health systems to expand structural heart programs.
TAVR is particularly significant for elderly and high-risk patients who may not tolerate open-heart surgery. The less invasive route reduces surgical trauma and accelerates recovery, helping hospitals manage capacity while improving patient outcomes.
Segment and Regional Dynamics
Mechanical heart valves led the product category in 2025, supported by durability, long lifespan, and reduced need for repeat surgery—characteristics that keep them relevant, especially for younger patients. The broader market spans mechanical, biological, and transcatheter heart valves, with valve repair and valve replacement remaining core treatment segments.
North America, led by the United States, dominated the market in 2025. Europe remains a key innovation gateway, with Edwards Lifesciences (搜索) launching the SAPIEN 3 Ultra RESILIA (搜索) valve in May 2024, featuring tissue technology designed to improve durability. China is gaining regulatory momentum, underscored by Genesis MedTech (搜索)'s NMPA approval for the J-Valve Transfemoral TAVI System (搜索) on September 17, 2025, creating a dedicated minimally invasive route for severe aortic regurgitation (搜索). India is entering the market through access and commercialization, with Foldax (搜索) launching the TRIA biopolymer mitral valve (搜索) in partnership with Dolphin Life Science LLP on September 3, 2025.
Competitive Landscape and Recent Developments
The competitive landscape is fragmented but led by companies with capital, clinical evidence, and manufacturing scale. Edwards Lifesciences (搜索) leads with advanced TAVI devices, Medtronic spans both TAVI and surgical valves, Boston Scientific is broadening its portfolio with new valve designs, and Abbott (搜索) remains visible through mitral valve repair.
Recent strategic developments underscore the market's dynamism. JenaValve (搜索) secured U.S. FDA premarket approval on March 18, 2026, for the Trilogy transcatheter heart valve system (搜索), creating a dedicated option for high-risk severe aortic regurgitation (搜索) patients. Medtronic received FDA approval and began rollout of the Mosaic Neo (搜索) bioprosthetic mitral valve on April 29, 2026, widening workflow flexibility across sternotomy and robotic implantation. Medtronic also agreed on January 21, 2026, to invest up to USD 90 million in Anteris Technologies (搜索), signaling confidence in late-stage biomimetic TAVR development.
Edwards Lifesciences (搜索) terminated its planned USD 945 million acquisition of JenaValve (搜索) on January 12, 2026, following U.S. Federal Trade Commission opposition, keeping competition open in the transcatheter aortic regurgitation (搜索) space.
Challenges and Strategic Outlook
Cost remains the primary restraint. Heart valve devices require expensive materials, precision manufacturing, clinical trials, and strict quality control, raising barriers for emerging companies and potentially slowing access where buyers cannot absorb premium pricing.
"Competition is shifting from product availability to procedural fit," MMR notes. Devices that handle difficult anatomy, reduce complications, and lower reintervention risk are positioned to gain influence. Komal Patil, Analyst at Maximize Market Research, stated: "Heart valve devices are moving from episodic surgery toward planned structural heart management. The winners will prove durability, secure approvals across major regions, and help hospitals treat older and higher-risk patients with less procedural burden."
The market is entering a scale phase in which leaders will combine regulatory access, durable design, procedural evidence, and hospital workflow fit. Hospitals are increasingly treating valve care as a service-line decision encompassing imaging, interventional cardiology, surgical backup, follow-up, and patient selection protocols—not merely a device purchase.